


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-24 (cancelled)

25. (new) A method of treating acute myeloid leukemia in a human patient which comprises treating the patient in need of such treatment simultaneously, concurrently, separately or sequentially with therapeutically effective amounts of (a) a FLT-3 inhibitor and (b) a histone deacetylase inhibitor, wherein the FLT-3 inhibitor is a compound of formula (VII)



(VII)

or a pharmaceutically acceptable salt thereof; and the histone deacetylase inhibitor is selected from the group consisting of *N*-hydroxy-3-[4-[[[(2-hydroxyethyl)]2-(1*H*-indol-3-yl)ethyl]-amino]methyl]phenyl]-2*E*-2-propenamide, and *N*-hydroxy-3-[4-[[[2-(2-methyl-1*H*-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2*E*-2-propenamide, or, in each case a pharmaceutically acceptable salt thereof.